Danaher Corp. closed 35.83% below its 52-week high of $281.70, which the company reached on August 1st.

Andvari Associates, an investment management firm, released its first-quarter 2025 investor letter. A copy of the letter can ...

We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Fintel reports that on April 10, 2025, Barclays upgraded their outlook for Danaher (NYSE:DHR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 40.08% Upside As of April 2, 2025, the ...

Barclays upgraded Danaher (DHR) to Overweight from Equal Weight with a price target of $205, down from $240. The firm cites its defensive ...

Valued at a market cap of $129.9 billion, Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, ...

Barclays analyst Luke Sergott upgraded Danaher (DHR – Research Report) to a Buy today and set a price target of $205.00. The company’s shares ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. Click here to read why I rate DHR ...

DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies.

Valued at a market cap of $129.9 billion, Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, research, and industrial products and services. This Washington ...